Speaker: Justin Byers, Founder & CEO of Axio BioPharma

Time: 10:10 am, January 20^th (Tuesday)

Topic: Accelerating Bioprocess Development with AI + Automation

Overview: At Axio BioPharma, innovation is guided by the mission to transform antibody discovery and development through AI-powered technology. To accelerate this vision, Founder and CEO Justin Byers adopted GenScript’s AmMag™ Quatro ProAb 1300, which has streamlined Axio’s antibody purification workflow and advanced the company’s approach to biomanufacturing.

Abstract: Bioprocess development faces increasing challenges from accelerated timelines, fragmented data, and process variability, leading to delayed patient access. This presentation explores how AI and high-quality data generation can address these challenges, introducing Axio’s federated approach to secure, collaborative learning. A case study featuring the GenScript Quatro ProAb 1300 highlights how automated purification accelerates antibody discovery and development through AI-powered workflows.